Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy

פריטים דומים

• Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
  מאת: Mundayat, Rajiv, et al.
  יצא לאור: (2018)
• Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
  מאת: Li, Benjamin, et al.
  יצא לאור: (2020)
• Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial
  מאת: Keohane, Denis, et al.
  יצא לאור: (2015)
• Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy
  מאת: Waddington-Cruz, Marcia, et al.
  יצא לאור: (2015)
• Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
  מאת: Waddington Cruz, Márcia, et al.
  יצא לאור: (2016)